A Pivotal Month for Novo Nordisk: Shareholder Votes and Strategic Shifts

Novo Nordisk faces key AGM vote and dividend ex-date as shares fall 74% from peak. Strategic moves include new weight-loss drug data and a $5.2B acquisition.

March presents a critical series of events for Novo Nordisk. The Danish pharmaceutical giant will hold its Annual General Meeting on March 26, followed by the dividend ex-date in Copenhagen the next day. These developments unfold against a challenging backdrop: the company's shares have declined approximately 74% from their mid-2024 peak, signaling a period of significant transition that raises both structural and strategic questions.

Strategic Levers and Pipeline Developments

Beyond immediate pressures, the company is activating several strategic initiatives. Phase II data for the experimental triple-agonist UBT251 demonstrated an average weight loss of up to 19.7% after 24 weeks, compared to 2% for the placebo group. While early-stage, these results are considered noteworthy.

Furthermore, the acquisition of Akero Therapeutics for up to $5.2 billion adds the candidate efruxifermin to Novo Nordisk's portfolio. This asset is currently in three ongoing Phase III studies for metabolic diseases. In parallel, the firm is investing €432 million to expand its production facility in Athlone, Ireland, aiming to increase capacity for GLP-1 treatments.

Management has also noted initial encouraging demand signals for the Wegovy pill, launched in the U.S. at an introductory price of $149—significantly below the injectable version's cost. Whether this volume-driven approach can offset price erosion will become clearer in quarterly results over the coming months.

The Weight of the Upcoming Annual General Meeting

This year's AGM carries substantial importance. The current share buyback program, approved at the 2025 AGM, will expire without renewed shareholder authorization. An extension is therefore explicitly on the ballot for approval.

The composition of the board of directors is also set for a partial refresh. Alongside the re-election of Lars Rebien Sørensen as Chair—who returned to the role following a turbulent leadership transition—the board has nominated three new members: Helena Saxon, Jan van de Winkel, and Ramona Sequeira.

Dividend Declaration Amid Share Price Decline

The final dividend for 2025 is set at 7.95 DKK per share, with an ex-date of March 27 and payment on March 31. For ADR holders on the NYSE, the payment is $1.2751 per share, with an ex-date of March 30 and payment on April 8.

The total dividend for 2025 reaches 11.70 DKK, marking a 2.6% increase over 2024 with a payout ratio of 50.7%. In the context of the severe share price depreciation, this continuity in shareholder returns is seen as a gesture with symbolic significance beyond the figures themselves.

Revised Forecasts and Shifting Analyst Sentiment

A primary source of pressure remains the outlook Novo Nordisk published in February 2026. Management anticipates a 5% to 13% decline in both sales and operating profit for 2026 at constant exchange rates. The company cited slowing growth in GLP-1 prescriptions, increasing competition from Eli Lilly, and pricing pressure from the U.S. "Most Favored Nations" pricing agreement as key drivers.

CEO Mike Doustdar stated bluntly: "People should expect it to go down before it goes back up."

Wall Street has responded to the stock's decline with a widespread reassessment:

• Morgan Stanley upgraded the equity to Equal-weight from Underweight, with a price target of $40 USD, noting the P/E ratio has compressed to approximately 11 times 2026 estimates.
• Goldman Sachs maintained a Neutral rating but lowered its 12-month price target from $63 to $41 USD, citing persistent pricing pressure risks for GLP-1 therapies.
• J.P. Morgan downgraded the stock to Neutral from Overweight, reducing its revenue forecasts for 2026–2030 by 2–16%, and pointed to disappointing CagriSema trial data.